A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effect of RO7795074 on how the body processes pitavastatin

2025-521921-34-00 Protocol BP45863 Human pharmacology (Phase I) - Other Ended

Start 19 Dec 2025 · End 13 May 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol BP45863

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 32
Countries 1
Sites 1

Overweight or Obese (otherwise healthy)

Key facts

Sponsor
Genentech Inc.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
19 Dec 2025 → 13 May 2026
Decision date (initial)
2025-12-01
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Overweight or Obese (otherwise healthy)

VersionLevelCodeTermSystem organ class
20.0 PT 10029883 Obesity 100000004861
24.1 PT 10033307 Overweight 100000004861

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Genentech Inc.

Sponsor organisation
Genentech Inc.
Address
1 Dna Way
City
South San Francisco
Postcode
94080-4918
Country
United States

Scientific contact point

Organisation
Genentech Inc.
Contact name
US Program Manager Product Development Regulatory

Public contact point

Organisation
Genentech Inc.
Contact name
US Program Manager Product Development Regulatory

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 32 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2025-12-19 2026-05-13 2025-12-19 2026-03-09

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-10-17 Netherlands Acceptable
2025-11-27
2025-12-01
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-12-18 Netherlands Acceptable
2025-11-27
2025-12-18
3 NON SUBSTANTIAL MODIFICATION NSM-2 2026-01-12 Netherlands Acceptable
2025-11-27
2026-01-12